

Jgrcvke"Gpegr jcnqrcvj {"=Rtgxcngpeg."Rtgekrkvcvkpi "Hcevqtu"cpf"Ejcmngpi gu"qh Ocpci g o gpv"kp"c"Tguqwteg/Nk o kvgf"Ugsvkpi

Kevin Charles Raphael¹, Sarah Shali Matuja¹, Nicole T Shen², Anthony C Liwa³ and Hyasinta Jaka^{1*}

¹Department of Internal Medicine-Gastroenterology and Hepatology Unit, Catholic University of Health and Allied Sciences, Bugando, Mwanza, Tanzania

²NewYork-Presbyterian Hospital, Weill Cornell Medical Center, New York, USA

³Department of Pharmacology, Catholic University of Health and Allied Sciences, Bugando, Mwanza, Tanzania

*Corresponding author: Hyasinta Jaka, Department of Internal Medicine-Gastroenterology and Hepatology Unit, Catholic University of Health and Allied Sciences, P.O.Box 1464, Bugando, Mwanza, Tanzania, Tel: +255-28-2500881; E-mail: yasintaliwa5@gmail.com

Received date: April 11, 2016; Acceptance date: June 10, 2016; Published date: June 16, 2016

Copyright: © 2016 Raphael KC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background and Aims: Hepatic encephalopathy, a neuropsychiatric syndrome caused by portosystemic venous shunting, clinical presentation ranges from minimal to overt H.E. It is a common complication of advanced liver disease with significant morbidity and mortality. The aim of this study was to assess the prevalence, common precipitating factors, and outcomes of hepatic encephalopathy in patients with preexisting liver disease.

Methods: A hospital based, retrospective chart review study was conducted at Bugando Medical Centre a tertiary hospital in Mwanza region. The target population included all patients aged > 18 years admitted with Hepatic encephalopathy from January 2009 to June 2015. Patients were enrolled using a detailed checklist, personal identifications were removed and analysis was done using the SPSS version 17.0.

Results: A population of 88 patients with Hepatic encephalopathy were enrolled with a mean of 47 years (SD +/-17 years). Among patients admitted to the medical ward, the prevalence was 0.4% (88/23942). Most common liver disease and complications including alcoholic cirrhosis, hepatitis B infection, and hepatocellular carcinoma were present in 47.7% of (42/88), 22.7% (20/88), and 23.9% (21/88) patients, respectively. Majority had West Haven grade 3, 36.4% (32/88), and grade 4, 18.2% (16/88).

Precipitating factors included diuretic therapy on patients with ascites 27.2% (44/162), infections 21.6% (35/162), blood transfusions, 16.7% (27/162), and upper gastrointestinal bleeding 17.3% (28/162). Most died during their hospitalization, 75% (66/88). The remaining 25% (22/88) were discharged. Majority of the cohort, 72.7% (64/88), had less than 3 months survival after diagnosis, while 27.3% (24/88) survived more than 1 year.

Conclusions: We found severe Hepatic encephalopathy presenting in patients with preexisting liver disease associated with poor outcomes, posing challenges in management and survival. The use of newer and superior agents like polyethylene glycol, identification of subclinical Hepatic encephalopathy and targeting early removal of precipitating factors is imperative. Screening those at risk of developing Hepatic encephalopathy would likely improve outcomes.

Keywords: Hepatic encephalopathy; West Haven; Tanzania

Introduction

Background

Hepatic Encephalopathy (H.E), defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction after exclusion of brain disease, is a common complication of advanced liver disease with significant morbidity and mortality [1]. The exact worldwide prevalence of hepatic encephalopathy remains unknown, and is possibly a result of differences in etiological factors, severity of the disease, and challenges in diagnosing minimal or sub-clinical H.E [2]. Studies in developed countries reveal minimal hepatic encephalopathy affects the quality of life in 70% of patients with liver cirrhosis [3]. Other studies report on overt H.E occurring in 30% to 45% of patients with cirrhosis and 10 to 20% of patients with

Transjugular Porto Systemic Shunts (TIPS) [4]. Local data in Nigeria reported a prevalence of H.E in 6% of patients admitted to the gastroenterology medical ward [5].

Common H.E precipitating factors include sepsis, gastrointestinal (GI) bleeding, constipation, and diuretic use, and once treated, H.E usually subsides significantly [6]. However, patient outcome relies on early identification.

Treatment of H.E targets reducing the ammonia load in the body. Commonly this is achieved with lactulose use, though polyethylene glycol (PEG) was recently shown to be superior to lactulose in treating H.E of hospitalized patients [7]. Targeting broad-spectrum activity

•QxÜ &

Rationale

Variable	Frequency	Percentage
Severity of H.E		
Grade 1	10	11.6
Grade 2	30	34
Grade 3	32	36.4
Grade 4	16	18.2
Type of H.E		
A	20	22.9

